ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021
Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 74 citations in OpenAlex.
- A narrative review of barrier-matched engineering of macrophages for solid tumor immunotherapy: design logic, translational barriers and clinical outlook.Translational cancer research · 2026Review
- Unfolding and Degradation of Micellar Immunodrug Carriers Derived From End Group Modified Aliphatic Poly(Carbonate)s with Acid-Responsive Ketal Side Groups.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- The Role of Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in the Tumor Microenvironment and Their Impact on Ovarian Cancer Survival and Therapy.Current oncology (Toronto, Ont.) · 2026Review
- Nanoparticles that modulate immune cells - an important strategy for the future treatment of tumors.Frontiers in immunology · 2026Review
- Negative regulators antagonizing antitumor innate immune pathways in lung cancer immune evasion.Frontiers in immunology · 2026Review
- Inhaled biologics for respiratory diseases: clinical potential and emerging technologies.Drug delivery and translational research · 2025Review
- Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges.Molecular biotechnology · 2025Review
- Targeting circulating tumor cell‒neutrophil interactions: nanoengineered strategies for inhibiting cancer metastasis.Journal of nanobiotechnology · 2025Review
- Chemoselective dual functionalization of proteins via 1,6-addition of thiols to trifunctional N-alkylpyridinium.Nature communications · 2025Article
- Unlocking the power of imidazoquinolines: recent advances in anticancer and immunotherapeutic strategies.Future medicinal chemistry · 2025Review
- Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines.Molecular cancer · 2025Review
- Role of toll-like receptors in pulmonary immunity: mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
- Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review.Frontiers in immunology · 2025Review
- Microbiome-macrophage crosstalk in the tumor microenvironment: implications for oral squamous cell carcinoma progression and therapy.Frontiers in immunology · 2025Review
- The role of tumor-associated macrophages in lung cancer.Frontiers in immunology · 2025Review
- Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls.Clinical and experimental medicine · 2024Review
- HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study.Antibody therapeutics · 2024Article
- Development of a Specific Aptamer-Modified Nano-System to Treat Esophageal Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Immune pathway through endometriosis to ovarian cancer.World journal of clinical oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-associated macrophages (TAMs) promote the immune suppressive microenvironment inside tumors and are, therefore, considered as a promising target for the next generation of cancer immunotherapies. To repolarize their phenotype into a tumoricidal state, the Toll-like receptor 7/8 agonist imidazoquinoline IMDQ is site-specifically and quantitatively coupled to single chain antibody fragments, so-called nanobodies, targeting the macrophage mannose receptor (MMR) on TAMs. Intravenous injection of these conjugates result in a tumor- and cell-specific delivery of IMDQ into MMR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.